Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
Biogen and partner Stoke Therapeutics presented 4-year open-label extension data for zorevunersen in Dravet syndrome, highlighting sustained reductions in seizures and continued improvements in cognition and behavior. Safety data indicated that 77% of patients remained in the study at the 4-year mark, with the drug generally well-tolerated despite frequent CSF protein elevations that did not lead to serious clinical manifestations.
Key figures
- Doses administered
- > 930
- Ole retention rate
- 77%
- Phase3 results date
- Q3 2027
- Csf protein elevation rate
- ~94%
- Continuation rate phase1 to ole
- 93%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.